Brussels, Belgium
October 15, 2007
Tomorrow, a delegation from
EuropaBio, the European
Biotechnology Industry Association, will host Vice-President
Günter Verheugen and Commissioner Janez Potočnik.
Industry leaders will underline the importance of biotechnology
as a corner stone for Europe's growth and jobs strategy. The
meeting will be mainly focused on the implementation of the Mid
Term Review of the European Strategy for Life Sciences and
Biotechnology and the need to achieve coherent policy across
Europe.
Key topics to be addressed are:
- Value of innovation and
the development of a patient centred public healthcare
system
- Market access and approval system for biotech products
- Access to renewable resources at world market prices for
the bio-based economy
- Adventitious Presence of GM materials in seeds and
commodities
- Possible solutions for the "funding crisis" in Europe
- The review of Clinical Trials Directive
- How to develop a European Sustainability Certification
System for biofuels
- Improving communication on green biotechnology
- Advanced Therapies: making the Regulation effective
- The need for "pull measures" for biobased products in
Europe
"The biotech industry is delighted
to welcome Commissioners Verheugen and Potočnik to discuss how
Europe's biotech industry can help stimulate growth and create
jobs across Europe" said Steen Riisgaard, President and CEO of
Novozymes and Chairman of EuropaBio. He continued: "Europe was
the first region in the world that has developed a Strategy for
Life Science and Biotechnology. This Strategy can serve as a
useful basis for policy makers and industry leaders to work
together to support a competitive biotech industry in Europe
while meeting today's challenges in innovative, economically
prudent and environmentally friendly ways."
EuropaBio, the European Association for Bioindustries, has 85
direct members operating worldwide, 12 associate members and 5
bioregions as well as 25 national biotechnology associations
representing some 1800 small and medium sized enterprises
involved in research and development, testing, manufacturing and
distribution of biotechnology products. |
|
